|
59
|
222
|
4qvyL |
Ycp beta5-a49t-mutant in complex with bortezomib |
|
63
|
241
|
4qv1G |
Ycp beta5-m45a mutant |
|
50
|
204
|
4r67J |
Human constitutive 20s proteasome in complex with carfilzomib |
|
67
|
233
|
4qz2M |
Ycp beta5-m45i mutant in complex with the epoxyketone inhibitor onx 0914 |
|
71
|
240
|
4qv3C |
Ycp beta5-m45v mutant |
|
62
|
195
|
4qz6J |
Ycp beta5-a49t-a50v double mutant in complex with the epoxyketone inhibitor onx 0914 |
|
67
|
244
|
4qwlB |
Ycp beta5-a50v mutant in complex with carfilzomib |
|
67
|
242
|
4qw6D |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
58
|
226
|
4qv8H |
Ycp beta5-c52f mutant |
|
60
|
195
|
4qzzJ |
Ycp in complex with omuralide |
|
61
|
231
|
4qwxE |
Ycp in complex with the epoxyketone inhibitor onx 0914 |
|
64
|
231
|
4qvnE |
Ycp beta5-m45v mutant in complex with bortezomib |
|
64
|
233
|
4qz0M |
Ycp beta5-m45v mutant in complex with the epoxyketone inhibitor onx 0914 |
|
58
|
222
|
4qwfH |
Ycp beta5-m45i mutant in complex with carfilzomib |
|
59
|
222
|
4qv3L |
Ycp beta5-m45v mutant |
|
70
|
250
|
4qz4A |
Ycp beta5-a49s mutant in complex with the epoxyketone inhibitor onx 0914 |
|
72
|
240
|
4qlsC |
Ycp in complex with tripeptidic epoxyketone inhibitor 11 |
|
57
|
222
|
4qwgH |
Ycp beta5-a49v mutant in complex with carfilzomib |
|
63
|
195
|
4qwiJ |
Ycp beta5-a49s-mutant in complex with carfilzomib |
|
66
|
233
|
4qv0M |
Ycp beta5-a49t-a50v-double mutant |
|
71
|
243
|
4qw7F |
Ycp beta5-m45t mutant in complex with carfilzomib |
|
68
|
212
|
4qbyK |
Ycp in complex with boc-ala-ala-ala-cho |
|
55
|
204
|
4qzwI |
Ycp beta5-c52f mutant in complex with the epoxyketone inhibitor onx 0914 |
|
64
|
231
|
4qltE |
Ycp in complex with tripeptidic epoxyketone inhibitor 2 (pr924) |
|
66
|
242
|
4qz2D |
Ycp beta5-m45i mutant in complex with the epoxyketone inhibitor onx 0914 |
|
59
|
222
|
4qw5H |
Ycp beta5-m45a mutant in complex with carfilzomib |
|
64
|
231
|
4quyE |
Ycp beta5-a49s-mutant |
|
70
|
240
|
4qw6C |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
70
|
243
|
4qvlF |
Ycp in complex with bortezomib |
|
64
|
231
|
4qv4E |
Ycp beta5-m45t mutant |
|
71
|
212
|
4qz4K |
Ycp beta5-a49s mutant in complex with the epoxyketone inhibitor onx 0914 |
|
60
|
196
|
4qw0N |
Ycp beta5-a49t-a50v-double mutant in complex with bortezomib |
|
62
|
195
|
4qv6J |
Ycp beta5-a49v mutant |
|
70
|
244
|
4qvwB |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
58
|
204
|
4qlvI |
Ycp in complex with tripeptidic epoxyketone inhibitor 17 |
|
57
|
204
|
4qv7I |
Ycp beta5-a50v mutant |
|
59
|
226
|
4qvwH |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
71
|
240
|
4qwxC |
Ycp in complex with the epoxyketone inhibitor onx 0914 |
|
63
|
241
|
4qw6G |
Ycp beta5-m45v mutant in complex with carfilzomib |
|
60
|
231
|
4qvmE |
Ycp beta5-m45a mutant in complex with bortezomib |
|
64
|
231
|
4qvwE |
Ycp beta5-a49s-mutant in complex with bortezomib |
|
71
|
243
|
4qluF |
Ycp in complex with tripeptidic epoxyketone inhibitor 9 |
|
66
|
241
|
4r17G |
Ligand-induced aziridine-formation at subunit beta5 of the yeast 20s proteasome |
|
71
|
240
|
4qvqC |
Ycp beta5-m45i mutant in complex with bortezomib |
|
60
|
196
|
4quxN |
Ycp beta5-a49t-mutant |
|
57
|
204
|
4qw1I |
Ycp beta5-a50v mutant in complex with bortezomib |
|
61
|
196
|
4qv4N |
Ycp beta5-m45t mutant |
|
61
|
231
|
4qvqE |
Ycp beta5-m45i mutant in complex with bortezomib |
|
63
|
241
|
4qlqG |
Ycp in complex with tripeptidic epoxyketone inhibitor 8 |
|
59
|
222
|
4qzzL |
Ycp in complex with omuralide |
